Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.

ABSTRACT: Oral nirmatrelvir plus ritonavir (Paxlovid^™) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of SARS-CoV-2, with ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir plus ritonavir reduced the risk of progression to severe COVID-19 in symptomatic, unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression to severe disease. The incidence of COVID-19-related hospitalization or death through day 28 was significantly lower with nirmatrelvir plus ritonavir than with placebo. The efficacy of nirmatrelvir plus ritonavir has also been demonstrated in the real

SUBMITTER: Blair HA 

PROVIDER: S-EPMC9734504 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature